Financière de Tubize TUB.BR
Financière de Tubize is a Belgian holding company that concentrates its investment in a single subsidiary, the pharmaceutical company UCB, from which it derives virtually all of its dividend income. Financière de Tubize is a holding with a single stake (UCB), which concentrates all risk. Its financial health is very weak (Net Debt/EBITDA of 16.46) and valuation is demanding (P/E 81.36), although earnings growth of 5.40% and a payout of 48.85% offer some stability. Momentum is very negative (-16.48% over 12 months).
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Financière de Tubize is a Belgian holding company that concentrates its investment in a single subsidiary, the pharmaceutical company UCB, from which it derives virtually all of its dividend income. Financière de Tubize is a holding with a single stake (UCB), which concentrates all risk. Its financial health is very weak (Net Debt/EBITDA of 16.46) and valuation is demanding (P/E 81.36), although earnings growth of 5.40% and a payout of 48.85% offer some stability. Momentum is very negative (-16.48% over 12 months).
Score by category
| Category | Score |
|---|---|
| Financial health | 1.7 |
| Quality / Moat | 1.6 |
| Valuation | 2.0 |
| Growth | 5.5 |
| Dividend | 5.3 |
| Momentum | 0.9 |
| Risk & Context | 8.2 |
OVERALL SCORE: 3.4/10
Context and risks
Moderate governance risk in Belgium. As a holding with a single stake (UCB), the structure is simple and transparent, but concentration in a single asset amplifies any UCB-specific risk.
News considered in the analysis
- Financière de Tubize (ENXTBR:TUB) After Half Year Earnings Is The Stock Now Too Pricey — Artículo de análisis tras resultados semestrales que cuestiona la valoración; opinión de un medio, no un hecho material nuevo, pero puede influir en el sentimiento a corto plazo.
Verdict: Hold or reduce: extreme leverage and high valuation make the risk/reward profile unfavorable, despite UCB's underlying quality.
Main risk: Total concentration in UCB: any negative news about the pharmaceutical company (patents, regulation, results) directly impacts the holding, amplified by leverage of 16.46x EBITDA.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →